Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
- Market Cap ₹ 161 Cr.
- Current Price ₹ 14.3
- High / Low ₹ 15.9 / 5.24
- Stock P/E 74.0
- Book Value ₹ 9.11
- Dividend Yield 0.00 %
- ROCE 2.45 %
- ROE 4.18 %
- Face Value ₹ 10.0
Pros
Cons
- Company has a low return on equity of 3.84% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.1.91 Cr.
- Company has high debtors of 282 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.05 | 0.10 | 0.09 | 0.05 | 0.08 | 0.08 | 0.13 | 0.11 | 0.00 | 0.00 | 24.55 | |
| 0.05 | 0.04 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | 0.07 | 0.09 | 0.14 | 0.23 | 23.67 | |
| Operating Profit | -0.01 | 0.01 | 0.04 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | -0.14 | -0.23 | 0.88 |
| OPM % | -25.00% | 20.00% | 40.00% | 33.33% | -40.00% | 0.00% | -12.50% | 46.15% | 18.18% | 3.58% | ||
| 0.01 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.09 | 1.91 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 |
| Profit before tax | 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.18 | 2.78 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 21.94% | ||
| 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.17 | 2.17 | |
| EPS in Rs | 0.00 | 0.01 | 0.07 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.01 | 0.07 | -0.13 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 86% |
| 5 Years: | 214% |
| 3 Years: | 507% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 194% |
| 3 Years: | 377% |
| TTM: | 1376% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 83% |
| 3 Years: | 23% |
| 1 Year: | 184% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 13.44 | 13.44 | 112.44 |
| Reserves | -12.20 | -12.19 | -12.11 | -12.08 | -12.10 | -12.09 | -12.10 | -12.05 | -12.03 | -11.92 | -12.10 | -9.93 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.20 | |
| 0.13 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 41.27 | |
| Total Liabilities | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 | 266.98 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 |
| 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.30 | 1.35 | 266.95 | |
| Total Assets | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 | 266.98 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.01 | -0.05 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | 0.11 | -0.13 | -222.03 | |
| -0.02 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | -0.06 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 | -0.02 | 222.20 | |
| Net Cash Flow | -0.02 | 0.01 | -0.02 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | -0.06 | 0.02 | 0.11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 281.74 | ||
| Inventory Days | 2,554.11 | |||||||||||
| Days Payable | 51.61 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,784.24 | ||
| Working Capital Days | -1,186.25 | -876.00 | 36.50 | 81.11 | 73.00 | 45.62 | 0.00 | 0.00 | 0.00 | 2,092.47 | ||
| ROCE % | 120.00% | -66.67% | 0.00% | -40.00% | 133.33% | 25.00% | 9.94% | -12.59% | 2.45% |
Documents
Announcements
-
Welcure Wins New ? 856 Million Export-Sourcing Orders From Giant Exim & Ravina International - Reg-30 Disclosure
1d - Welcure wins ₹856M export sourcing orders from Giant Exim and Ravina International, boosting margins.
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025 till 48 hours post Q1 financial results disclosure.
-
Intimation Under Regulation 30 - Rs. 517 Crore Global Sourcing Mandate
18 Jun - ₹517 Cr overseas sourcing mandate with ₹25.85 Cr revenue over FY26, enhancing fee-based portfolio.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
17 Jun - Approved Managing Director appointment, expanded business scope, and increased authorized share capital to Rs.186 crore.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report for FY25; minor non-compliances fined and resolved.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.